

Anti-SARS-CoV-2 antibodies

Portuguese Society of Laboratory Medicine (SPML) recommendation


Antibodies in response to SARS-CoV-2 mRNA or viral vector-based vaccines only recognize the Spike protein, contrary to those elicited by infection that potentially recognize other viral proteins (including Spike).

As the commercially available tests use different target antigens (usually Spike or Nucleocapsid), it is mandatory for the test target to be known for its correct interpretation.

The Portuguese Society of Laboratory Medicine recommends all the Clinical Laboratories to state in their results the kind of antibodies tested.

As a suggestion, a terminology like “Anti-Spike SARS-CoV-2 antibodies” and “Anti-Nucleocapsid SARS-CoV-2 antibodies” could be used.

Isotype specificity (IgG, IgM, IgA or total) should also be stated.


João Faro Viana
SPML President